$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso

$ekso Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000114420417025646 Filed on May 09, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q1
Revenue	$1.867M	$1.436M	$8.486M
YoY Change	20.3%	-83.08%	402.43%
Cost Of Revenue	$1.471M	$1.077M	$319.0K
YoY Change	9.04%	237.62%	-75.19%
Gross Profit	$396.0K	$352.0K	$1.498M
YoY Change	95.07%	-76.5%	271.71%
Gross Profit Margin	21.21%	24.51%	17.65%
Selling, General & Admin	$5.745M	$5.620M	$5.990M
YoY Change	6.82%	-6.18%	70.66%
% of Gross Profit	1450.76%	1596.59%	399.87%
Research & Development	$2.632M	$2.870M	$2.149M
YoY Change	18.51%	33.55%	118.62%
% of Gross Profit	664.65%	815.34%	143.46%
Depreciation & Amortization	$400.0K	$475.0K	$440.0K
YoY Change	-14.89%	7.95%	120.0%
% of Gross Profit	101.01%	134.94%	29.37%
Operating Expenses	$8.855M	$8.500M	$8.140M
YoY Change	16.53%	4.42%	81.05%
Operating Profit	-$8.459M	-$8.148M	-$6.642M
YoY Change	14.37%	22.67%	62.28%
Interest Expense	$198.0K	$119.0K	$6.000K
YoY Change	-682.35%	1883.33%	-127.27%
% of Operating Profit
Other Income/Expense, Net	$2.952M	-$70.00K	$2.991M
YoY Change	80.99%	-102.34%	-13104.35%
Pretax Income	-$5.510M	-$8.300M	-$3.650M
YoY Change	-4.51%	127.4%	-11.41%
Income Tax
% Of Pretax Income
Net Earnings	-$5.507M	-$8.302M	-$3.651M
YoY Change	-4.48%	127.39%	-11.28%
Net Earnings / Revenue	-294.97%	-578.13%	-43.02%
Basic Earnings Per Share			-$0.44
Diluted Earnings Per Share	-$3.241M	-$0.38	-$0.44
COMMON SHARES
Basic Shares Outstanding	25.63M shares	21.90M shares	15.39M shares
Diluted Shares Outstanding		21.90M shares	15.39M shares

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.70M	$9.430M	$12.31M
YoY Change	129.61%	-23.4%	-41.74%
Cash & Equivalents	$10.70M	$9.426M	$12.31M
Short-Term Investments
Other Short-Term Assets	$600.0K	$740.0K	$1.000M
YoY Change	-13.04%	-26.0%	-53.05%
Inventory	$1.896M	$1.819M	$2.531M
Prepaid Expenses
Receivables	$2.107M	$1.282M	$2.383M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$15.30M	$13.26M	$18.22M
YoY Change	63.3%	-27.22%	-28.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.562M	$2.460M	$2.617M
YoY Change	-0.7%	-6.0%	19.88%
Goodwill	$189.0K		$189.0K
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$118.0K	$92.00K	$93.00K
YoY Change	31.11%	-1.08%	69.09%
Total Long-Term Assets	$3.631M	$3.633M	$4.330M
YoY Change	-13.75%	-16.1%	-3.41%
TOTAL ASSETS
Total Short-Term Assets	$15.30M	$13.26M	$18.22M
Total Long-Term Assets	$3.631M	$3.633M	$4.330M
Total Assets	$18.93M	$16.90M	$22.55M
YoY Change	39.41%	-25.08%	-24.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.068M	$2.867M	$3.618M
YoY Change	-0.1%	-20.76%	147.13%
Accrued Expenses	$2.458M	$2.747M	$2.928M
YoY Change	15.4%	-6.18%	76.7%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$972.0K	$389.0K	$80.00K
YoY Change	1115.0%	386.25%	100.0%
Total Short-Term Liabilities	$6.587M	$7.021M	$7.849M
YoY Change	13.77%	-10.55%	17.01%
LONG-TERM LIABILITIES
Long-Term Debt	$5.906M	$6.635M	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$73.00K	$87.00K	$205.0K
YoY Change	-98.83%	-57.56%	-95.07%
Total Long-Term Liabilities	$5.979M	$6.722M	$205.0K
YoY Change	-3.87%	3179.02%	-95.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.587M	$7.021M	$7.849M
Total Long-Term Liabilities	$5.979M	$6.722M	$205.0K
Total Liabilities	$17.30M	$18.28M	$15.80M
YoY Change	44.08%	15.7%	44.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$128.8M	-$123.3M	-$95.04M
YoY Change		29.77%	25.19%
Common Stock	$26.00K	$22.00K	$109.0K
YoY Change	62.5%	-79.82%	6.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.628M	-$1.383M	$6.753M
YoY Change
Total Liabilities & Shareholders Equity	$18.93M	$16.90M	$22.55M
YoY Change	39.41%	-25.08%	-24.91%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$5.507M	-$8.302M	-$3.651M
YoY Change	-4.48%	127.39%	-11.28%
Depreciation, Depletion And Amortization	$400.0K	$475.0K	$440.0K
YoY Change	-14.89%	7.95%	120.0%
Cash From Operating Activities	-$9.610M	-$7.254M	-$6.790M
YoY Change	31.11%	6.83%	77.28%
INVESTING ACTIVITIES
Capital Expenditures	-$110.0K	$138.0K	$285.0K
YoY Change	-64.52%	-51.58%	1.42%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$110.0K	-$138.0K	-$290.0K
YoY Change	-64.52%	-52.41%	3.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.92M	$2.000K	-160.0K
YoY Change	-109300.0%	-101.25%	-420.0%
NET CHANGE
Cash From Operating Activities	-9.610M	-$7.254M	-6.790M
Cash From Investing Activities	-110.0K	-$138.0K	-290.0K
Cash From Financing Activities	10.92M	$2.000K	-160.0K
Net Change In Cash	1.200M	-$7.390M	-7.240M
YoY Change	-115.69%	2.07%	78.33%
FREE CASH FLOW
Cash From Operating Activities	-$9.610M	-$7.254M	-$6.790M
Capital Expenditures	-$110.0K	$138.0K	$285.0K
Free Cash Flow	-$9.500M	-$7.392M	-$7.075M
YoY Change	35.33%	4.48%	72.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	43000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	20684000	USD
CY2017Q1	us-gaap	Assets Assets	16895000	USD
CY2016Q4	us-gaap	Assets Assets	24425000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2867000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7021000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6314000	USD
CY2017Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	776000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	92000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	91000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1879000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2747000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3556000	USD
CY2017Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	975000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	825000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	805000	USD
CY2017Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	87000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	107000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	18278000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	17894000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	22000	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	22000	USD
CY2017Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	121880000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	121291000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-123334000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-114861000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	-1383000	USD
CY2016Q1	us-gaap	Depreciation Depreciation	440000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	475000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	394000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-4335000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	46000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1475000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	298000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	188000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	314000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	470000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-498000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	924000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	988000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1255000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-808000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-6585000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	121000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-7238000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-7420000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12314000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	285000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	138000	USD
CY2016Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	19000	USD
CY2017Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	22000	USD
CY2017Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-30000	USD
CY2016Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
CY2017Q1	us-gaap	Preferred Stock Amount Of Preferred Dividends In Arrears PreferredStockAmountOfPreferredDividendsInArrears	0	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	6531000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24425000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	13262000	USD
CY2016Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	0	USD
CY2017Q1	us-gaap	Deferred Costs Current DeferredCostsCurrent	46000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	502000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16895000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	689000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	1556000	USD
CY2017Q1	us-gaap	Inventory Net InventoryNet	1819000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1780000	USD
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1282000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16846000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9426000	USD
CY2016Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	54000	USD
CY2017Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	217000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	217000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	49000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	79000	USD
CY2017Q1	ekso	Business Combination Contingent Success Fee Liability BusinessCombinationContingentSuccessFeeLiability	117000	USD
CY2016Q4	ekso	Business Combination Contingent Success Fee Liability BusinessCombinationContingentSuccessFeeLiability	116000	USD
CY2017Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	6445000	USD
CY2016Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	6789000	USD
CY2016Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	429000	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	8486000	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	1436000	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	6669000	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1077000	USD
CY2016Q1	us-gaap	Preferred Stock Amount Of Preferred Dividends In Arrears PreferredStockAmountOfPreferredDividendsInArrears	3124000	USD
CY2016Q1	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	2985000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-30000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
CY2017Q1	us-gaap	Long Term Debt And Capital Lease Obligations Repayments Of Principal In Next Twelve Months LongTermDebtAndCapitalLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths	38000	USD
CY2017Q1	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Two LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo	37000	USD
CY2017Q1	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Three LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree	37000	USD
CY2017Q1	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Four LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour	22000	USD
CY2017Q1	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Five LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive	0	USD
CY2017Q1	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal After Year Five LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive	0	USD
CY2016Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	96000	USD
CY2017Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	101000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8332000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6775000	USD
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21899000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15388000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21920000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15388000	shares
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6789000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1574000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-138000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19552000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-7254000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-285000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-164000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2000	USD
CY2017Q1	ekso	Unrestricted Cash And Cash Equivalents UnrestrictedCashAndCashEquivalents	2748000	USD
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	6678000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7373000	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4058000	shares
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	21000	shares
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2017Q1	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	50000	USD
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	71429000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21902000	shares
CY2017Q1	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	134000	USD
CY2017Q1	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	9000	USD
CY2017Q1	us-gaap	Capital Lease Obligations CapitalLeaseObligations	125000	USD
CY2017Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	82000	USD
CY2016Q4	ekso	Product Maintenance Warranty Liabilities Current Noncurrent ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent	687000	USD
CY2017Q1	ekso	Product Maintenance Warranty Expense ProductMaintenanceWarrantyExpense	-126000	USD
CY2017Q1	ekso	Product Maintenance Warranty Liabilities Current Noncurrent ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent	561000	USD
CY2017Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1581000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2349000	USD
CY2017Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	56000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	56000	USD
CY2017Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	157000	USD
CY2016Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	203000	USD
CY2017Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	183000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	110000	USD
CY2017Q1	ekso	Accrued Maintenance Current AccruedMaintenanceCurrent	404000	USD
CY2016Q4	ekso	Accrued Maintenance Current AccruedMaintenanceCurrent	483000	USD
CY2017Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	366000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	355000	USD
CY2017Q1	us-gaap	Deferred Revenue DeferredRevenue	1751000	USD
CY2016Q4	us-gaap	Deferred Revenue DeferredRevenue	1630000	USD
CY2017Q1	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	46000	USD
CY2016Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	0	USD
CY2017Q1	us-gaap	Deferred Costs DeferredCosts	0	USD
CY2016Q4	us-gaap	Deferred Costs DeferredCosts	0	USD
CY2017Q1	us-gaap	Deferred Rent Credit DeferredRentCredit	93000	USD
CY2016Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	60000	USD
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	EKSO BIONICS HOLDINGS, INC.
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001549084
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q1	dei	Trading Symbol TradingSymbol	EKSO
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25634568	shares
CY2017Q1	us-gaap	Notes Payable Current NotesPayableCurrent	389000	USD
CY2016Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	71429000	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21902000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21894000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21894000	shares
CY2017Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-92000	USD
CY2016Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	6000	USD
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b>Use of Estimates</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to: revenue recognition, deferred revenue and the deferral of the associated costs, future warranty costs, maintenance and planned improvement costs associated with medical device units sold prior to 2016, useful lives assigned to long-lived assets, realizability of deferred tax assets, the valuation of options and warrants, and contingencies. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b>Concentration of Credit Risk and Other Risks and Uncertainties</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. We maintain our cash accounts in excess of federally insured limits. However, we believe we are not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held.  We extend credit to customers in the normal course of business and perform ongoing credit evaluations of our customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. We do not require collateral from our customers to secure accounts receivable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Accounts receivable are derived from the sale of products shipped to and services performed for customers. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and records an allowance for credit losses, as needed. The Company has not experienced any material losses related to accounts receivable as of March 31, 2017 and December 31, 2016.</div>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, we have not experienced significant gains or losses upon settling foreign currency denominated accounts receivable.</div>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">As of March 31, 2017, we had three customers with an accounts receivable balance totaling <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% or more of our total accounts receivable (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11</font>%, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>%) compared with three customers as of December 31, 2016 (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18</font>%, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 16</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11</font>%).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">In the three months ended March 31, 2017, we had one customer with billed revenue of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% or more of total billed revenue (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">26</font>%), compared with four customers in the three months ended March 31, 2016 (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">27</font>%, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20</font>%, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>%).</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q1	us-gaap	Accretion Expense AccretionExpense	24000	USD
CY2016Q1	us-gaap	Accretion Expense AccretionExpense	0	USD
CY2017Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2016Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	173000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	24000	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	28000	USD
CY2017Q1	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	0	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-30000	USD
CY2017Q1	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	-30000	USD
CY2017Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1156000	USD
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1193000	USD
CY2017Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	395000	USD
CY2016Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	198000	USD
CY2017Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	370000	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	267000	USD
CY2017Q1	us-gaap	Inventory Gross InventoryGross	1921000	USD
CY2016Q4	us-gaap	Inventory Gross InventoryGross	1658000	USD
CY2017Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	102000	USD
CY2016Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	102000	USD
CY2017Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	389000	USD
CY2017Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	6635000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1610000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	716000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	894000	USD
CY2017Q1	us-gaap	Debt Instrument Unused Borrowing Capacity Amount DebtInstrumentUnusedBorrowingCapacityAmount	3000000	USD
CY2016Q4	ekso	Success Fee Expenses SuccessFeeExpenses	250000	USD
CY2016Q4	us-gaap	Share Price SharePrice	8.00
CY2016Q4	ekso	Contingent Success Fee Liability ContingentSuccessFeeLiability	117000	USD
CY2017Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0878	pure
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	404000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	490000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.82	pure
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	6206000	USD
CY2017Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-7 reverse
CY2016Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	3546000	USD
CY2016Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	69000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0205	pure
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0240	pure
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0124	pure
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0178	pure
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8	pure
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.77	pure
CY2017Q1	ekso	Class Of Warrant Or Right Expiration Term ClassOfWarrantOrRightExpirationTerm	P5Y
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	394000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1574000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2017Q1	ekso	Amortization Of Deferred Rent AmortizationOfDeferredRent	9000	USD
CY2016Q1	ekso	Amortization Of Deferred Rent AmortizationOfDeferredRent	9000	USD
CY2017Q1	ekso	Warrants To Purchase Common Stock Expiration During Period WarrantsToPurchaseCommonStockExpirationDuringPeriod	371000	shares
CY2016Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3597000	shares
CY2017Q1	ekso	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	0	shares
CY2017Q1	ekso	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	-371000	shares
CY2017Q1	ekso	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	0	shares
CY2017Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3226000	shares

Files In Submission

Name	View Source	Status
0001144204-17-025646-index-headers.html	Edgar Link	pending
0001144204-17-025646-index.html	Edgar Link	pending
0001144204-17-025646.txt	Edgar Link	pending
0001144204-17-025646-xbrl.zip	Edgar Link	pending
ekso-20170331.xml	Edgar Link	completed
ekso-20170331.xsd	Edgar Link	pending
ekso-20170331_cal.xml	Edgar Link	unprocessable
ekso-20170331_def.xml	Edgar Link	unprocessable
ekso-20170331_lab.xml	Edgar Link	unprocessable
ekso-20170331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v465437_10q.htm	Edgar Link	pending
v465437_ex31-1.htm	Edgar Link	pending
v465437_ex31-2.htm	Edgar Link	pending
v465437_ex32-1.htm	Edgar Link	pending
v465437_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso

2017 Q2 Form 10-Q Financial Statement

#000114420417025646 Filed on May 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EKSO EKSO BIONICS HOLDINGS, INC. Stock $ekso

2017 Q2 Form 10-Q Financial Statement

#000114420417025646 Filed on May 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso